ZTS

79.5101.58%
FA

Frank A. D'Amelio

Independent Director

Mr. Frank A. D'Amelio, M.B.A is Independent Director of Metaphore Biotechnologies, Inc. from November 2026. Mr. D'Amelio is Independent Director of Hewlett Packard Enterprise Company from January 10, 2023. He is Independent Director at Humana Inc. since September 2003. Mr. D’Amelio is Director of Sail Biomedicines, Inc. Mr. D’Amelio is the former Executive Vice President & Chief Financial Officer at Pfizer, Inc, responsible for all corporate finance functions including audit, treasury, tax, investor relations, insurance, operations planning and analysis, corporate controllership and business finance and analytics. From 2019 through 2021, Mr. D’Amelio was the Chief Financial Officer & Executive Vice President, Global Supply responsible for Pfizer’s worldwide global supply chain. This included the manufacture, storage and distribution of the COVID vaccine. More than 3B doses of the COVID vaccine were made in the first year of production. During his time at Pfizer, Mr. D’Amelio was also responsible for business operations which included IT, procurement, real estate and business development. At Pfizer, Mr. D’Amelio led the acquisition and integration of Wyeth Pharmaceuticals, King Pharmaceuticals, Hospira Inc., Anacor Pharmaceuticals, Inc., Medivation, Inc. and Array, as well as the spin-off of Pfizer’s animal health business, Zoetis, the sale of its nutrition business to Nestle and its Capsugel business to KKR, the formation of the Consumer JV Haleon with GSK and the formation of Viatris with Mylan. During Mr. D’Amelio's tenure as the Pfizer CFO, Pfizer’s market cap increased by 165B. Including the Zoetis spin-off, market cap increased by approximately 250B. Further, Mr. D’Amelio has completed business development transactions totaling approximately 200B. He served as Senior Vice President and CFO from 2007 to December 2010 at Pfizer. Before joining Pfizer as CFO in September 2007, Mr. D’Amelio was Senior Executive Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent, responsible for the integration of the Alcatel-Lucent merger as well as procurement, real estate, IT and supply chain. Prior to the merger of Alcatel and Lucent Technologies in 2006, Mr. D’Amelio was the Chief Operating Officer of Lucent Technologies. He serves as Director of EntityRisk, Inc from 2023. In 2001, he was appointed Executive Vice President and Chief Financial Officer of Lucent, where he helped lead the company through one of the most challenging periods in the telecom industry’s history and returned the company to profitability. When Lucent was spun off from AT&T in 1996, He helped create the new company financially as the CFO of Lucent’s Network Systems Business and was a critical member of the team that met with investors around the world during Lucent’s initial public offering. In 1999, he was appointed the Group President of Lucent’s Switching Solutions Business Unit, where he led Lucent’s multibillion-dollar, global Switching, Access and Application Software business. Born and raised in New Jersey, He started his career in 1979 at Bell Labs, holding a variety of financial, accounting and general management positions and moved within AT&T, holding a series of positions with increasing responsibility. In 2005, 2006, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020 and 2021 Mr. D’Amelio was ranked among America’s top CFOs by Institutional Investor magazine. He serves on the Boards of Directors of Zoetis, Inc.; Hewlett Packard Enterprises; Catalent, Inc. and is the CFO-in-Residence, Independent Advisor, Deloitte LLP. Mr. D’Amelio earned his MBA in Finance from St. John’s University and his bachelor’s degree in Accounting from St. Peter’s University.

Positions